We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for HNSCC patients undergoing platinum-based induction chemotherapy. The gene discussed is ERCC1; the disease is head and neck squamous cell carcinoma.